[1]刘 洪.地特胰岛素或甘精胰岛素联合使用口服药物治疗2型糖尿病疗效及对体重的影响分析[J].医学信息,2018,31(09):135-137.[doi:10.3969/j.issn.1006-1959.2018.09.042]
　LIU Hong.Effect of Insulin Detemir or Insulin Glargine Combined with Oral Medication on Type 2 Diabetes Mellitus and its Influence on Body Weight[J].Journal of Medical Information,2018,31(09):135-137.[doi:10.3969/j.issn.1006-1959.2018.09.042]
点击复制

地特胰岛素或甘精胰岛素联合使用口服药物治疗2型糖尿病疗效及对体重的影响分析()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
31卷
期数:
2018年09期
页码:
135-137
栏目:
药物与临床
出版日期:
2018-05-01

文章信息/Info

Title:
Effect of Insulin Detemir or Insulin Glargine Combined with Oral Medication on Type 2 Diabetes Mellitus and its Influence on Body Weight
文章编号:
1006-1959（2018）09-0135-03
作者:
刘 洪
四川省科学城医院内分泌科，四川 绵阳 621900
Author(s):
LIU Hong
Department of Endocrinology,Sichuan Science City Hospital,Mianyang 621900,Sichuan,China
关键词:
2型糖尿病; 地特胰岛素; 体重增加少
Keywords:
Key words：Diabetes mellitus type 2; Insulin detemir; Less weight gain
分类号:
R587.1
DOI:
10.3969/j.issn.1006-1959.2018.09.042
文献标志码:
A
摘要:
目的 观察地特胰岛素或甘精胰岛素联合口服药物治疗T2DM的疗效及对体重的影响。方法 80例T2DM患者随机分为Det组和Gla组，每组40例。Det组采用阿卡波糖+二甲双胍+地特胰岛素治疗，Gla组采用阿卡波糖+二甲双胍+甘精胰岛素治疗。治疗12周后对比两组患者治疗前后HbA1C、FPG、2hPG、基础胰岛素用量、体重变化以及低血糖发生率。结果 两组患者FPG、2hPG及HbA1C均到有效控制，Det组HbA1C由（9.6±2.1）%降至（6.8±0.6）%，Gla组HbA1C由（9.2±2.1）%降至（6.4±0.7）%。Det组及Gla组FPG分别由（10.5±2.3）mmol/L、（10.6±2.4）mmol/L降至（6.1±0.6）mmol/L、（6.3±0.7）mmol/L；2hPG分别由（14.9±2.3）mmol/L、（14.5±2.1）mmol/L降至（9.1±1.1）mmol/L、（9.2±1.3）mmol/L，差异均具有统计学意义（P＜0.05）。达到同样空腹血糖水平，Det组基础胰岛素用量为（0.40±0.05）U/kg，少于Gla组的（0.60±0.04）U/kg，差异具有统计学意义（P＜0.05）。治疗12周后，Det组体重增加（1.3±0.4）kg，Gla组体重增加（2.5±0.3）kg，Det组体重增加低于Gla组，差异具有统计学意义（P＜0.05）。Gla组低血糖发生率为5.00%，Det组低血糖发生率为2.50%，两组间比较，差异无统计学意义（P＞0.05）。结论 T2DM患者口服药物联合基础胰岛素控糖是一种安全有效的选择，地特胰岛素对体重增加方面更有优势。
Abstract:
Abstract：Objective To observe the effect of insulin or insulin glargine combined with oral drugs on T2DM and its effect on body weight.Methods 80 patients with T2DM were randomly divided into Det group and Gla group,40 cases in each group.Group Det was treated with acarbose+metformin+insulin.Gla group was treated with acarbose+metformin plus+glargine.After treatment for 12 weeks,the HbA1C,FPG,2hPG,basal insulin dosage,body weight and incidence of hypoglycemia were compared between the two groups before and after treatment.Results Both FPG,2hPG,and HbA1C were effectively controlled in both groups, HbA1C in the Det group decreased from(9.6±2.1)% to(6.8±0.6)%,and HbA1C in the Gla group decreased from(9.2±2.1)% to(6.4±0.7)%.FPG in Det group and Gla group decreased from(10.5±2.3)mmol/L,(10.6±2.4)mmol/L to(6.1±0.6)mmol/L,(6.3±0.7)mmol/L, respectively;2hPG decreased from(14.9±2.3)mmol/L and(14.5±2.1)mmol/L to(9.1±1.1) mmol/L and(9.2±1.3)mmol/L,respectively,with statistical significance(P<0.05).To achieve the same fasting blood glucose level,the basal insulin dosage in the Det group was(0.40±0.05)U/kg,which was lower than that in the Gla group(0.60±0.04)U/kg,and the difference was statistically significant (P<0.05).After 12 weeks of treatment,the body weight of Det group increased(1.3±0.4)kg,while that of Gla group increased(2.5±0.3)kg.The weight gain of Det group was lower than that of Gla group,and the difference was statistically significant(P<0.05).The incidence of hypoglycemia was 5.00% in the Gla group and 2.50% in the Det group.There was no significant difference between the two groups(P>0.05).Conclusion Oral administration of T2DM in combination with basal insulin control is a safe and effective choice,insulin detemir has an advantage in weight gain.

参考文献/References:

[1]李延兵,马建华,母义明.2型糖尿病短期胰岛素强化治疗临床专家指导意见[J].药品评价,2017,14(9):5-12.
[2]黄文森.地特胰岛素与甘精胰岛素治疗老年2型糖尿病的疗效对比[J].中国老年学杂志,2014,8(34):4212-4214.
[3]Garber AJ,Abrahamson MJ,Barzilay JI,et al.Consensus statement by the american association of clinical endocrinologists American college of endocrinology insulin pump management task force[J].Endocr Pract,2017,23(2):207-238.
[4]Marathe PH,Gao HX,Close KL.American Diabetes Association.Standards of medical care in diabetes 2017[J].J Diabetes,2017,9(4):320-324.
[5]陆菊明.回到基础--地特胰岛素的安全性评价[J].中国糖尿病杂志,2012,20(8):638-640.
[6]Ji L,Zhang P,Zhu D,et al.Comparative effectiveness and safety of different basal insulins in a real-world setting[J].Diabetes Obes Metab,2017,19(8):1116-1126.
[7]Ji L,Zhang P,Weng J,et al.Observational Registry of Basal Insulin Treatment(ORBIT)in Patients with Type 2 Diabetes Uncontrolled by Oral Hypoglycemic Agents in China Study Design and Baseline Characteristics[J].Diabetes Technol Ther,2015,17(10):735-744.
[8]沈洁.地特胰岛素减少体重增加的可能机制与临床应用[J].中国糖尿病杂志,2010,8(3):238-240.
[9]Begg DP,May AA,Mul JD,et al.InsulinDetemir Is Transported From Blood to Cerebrospinal Fluid and Has Prolonged Central Anorectic Action Relative to NPH Insulin[J].Diabetes,2015,64(7):2457-2466.
[10]杨东明,闫萍,何华伟,等.地特胰岛素联合低剂量二甲双胍、阿卡波糖治疗老年2型糖尿病超重与肥胖患者疗效及安全性的观察[J].中国糖尿病杂志,2014,22(2):151-153.

相似文献/References:

[1]黄德斌,章臻翊,章 婷,等.2型糖尿病患者亚临床甲状腺功能减退与白蛋白尿的关系研究[J].医学信息,2018,31(02):88.[doi:10.3969/j.issn.1006-1959.2018.02.030]
　HUANG De-bin,ZHANG Zhen-yi,ZHANG Ting,et al.Relationship between Subclinical Hypothyroidism and Albuminuria in Patients with Type 2 Diabetes Mellitus[J].Journal of Medical Information,2018,31(09):88.[doi:10.3969/j.issn.1006-1959.2018.02.030]
[2]邓婷婷,王亚洲,张 红.口福怡稻治疗2型糖尿病的临床效果研究[J].医学信息,2018,31(03):116.[doi:10.3969/j.issn.1006-1959.2018.03.039]
　DENG Ting-ting,WANG Ya-zhou,ZHANG Hong.Clinical Study on the Treatment of Type 2 Diabetes Mellitus with Kou Fuyi Dao[J].Journal of Medical Information,2018,31(09):116.[doi:10.3969/j.issn.1006-1959.2018.03.039]
[3]曹岚,侯瑞田,王福慧,等.Lp-PLA2血小板相关因子与2型糖尿病合并高血压病的 相关性研究[J].医学信息,2018,31(05):3.[doi:10.3969/j.issn.1006-1959.2018.05.002]
　CAO Lan,HOU Rui-tian,WANG Fu-hui,et al.Study on the Correlation between Lp-PLA2 Platelet-associated Factors and Type 2 Diabetes Mellitus Complicated with Hypertension[J].Journal of Medical Information,2018,31(09):3.[doi:10.3969/j.issn.1006-1959.2018.05.002]
[4]靳雪芹,邓正聪.代谢综合征与肿瘤关系的研究进展[J].医学信息,2018,31(05):35.[doi:10.3969/j.issn.1006-1959.2018.05.014]
　JIN Xue-qin,DENG Zheng-cong.Research Progress on the Relationship between Metabolic Syndrome and Tumor[J].Journal of Medical Information,2018,31(09):35.[doi:10.3969/j.issn.1006-1959.2018.05.014]
[5]郭云飞,王亚柱,刘 超,等.血浆致动脉硬化指数与冠心病合并2型糖尿病的相关性分析[J].医学信息,2022,35(09):108.[doi:10.3969/j.issn.1006-1959.2022.09.027]
　GUO Yun-fei,WANG Ya-zhu,LIU Chao,et al.Correlation Between Plasma Arteriosclerosis Index and Coronary Heart Disease Complicated with Type 2 Diabetes Mellitus[J].Journal of Medical Information,2022,35(09):108.[doi:10.3969/j.issn.1006-1959.2022.09.027]
[6]徐晨曦.达格列净联合DPP-4抑制剂与二甲双胍对血糖控制不佳2型糖尿病患者血糖及脂代谢的影响[J].医学信息,2022,35(09):165.[doi:10.3969/j.issn.1006-1959.2022.09.042]
　XU Chen-xi.Effects of Daglitazone Combined with DPP-4 Inhibitor and Metformin on Blood Glucose and Lipid Metabolism in Patients with Type 2 Diabetes Mellitus with Poor Glycemic Control[J].Journal of Medical Information,2022,35(09):165.[doi:10.3969/j.issn.1006-1959.2022.09.042]
[7]余 佳.早期胰岛素强化治疗对初诊2型糖尿病患者血糖控制效果及颈动脉粥样硬化进展的影响[J].医学信息,2022,35(10):140.[doi:10.3969/j.issn.1006-1959.2022.10.034]
　YU Jia.Effect of Early Intensive Insulin Therapy on Blood Glucose Control and Progression of Carotid Atherosclerosis in Newly Diagnosed Type 2 Diabetic Mellitus Patients[J].Journal of Medical Information,2022,35(09):140.[doi:10.3969/j.issn.1006-1959.2022.10.034]
[8]张剑君.2型糖尿病参与血管衰老的机制[J].医学信息,2022,35(11):37.[doi:10.3969/j.issn.1006-1959.2022.11.011]
　ZHANG Jian-jun.The Mechanism of Type 2 Diabetes Mellitus in Vascular Aging[J].Journal of Medical Information,2022,35(09):37.[doi:10.3969/j.issn.1006-1959.2022.11.011]
[9]刘静波,黄 萍,赵 静.应用微信平台对初发中青年2型糖尿病患者进行 健康管理模式的研究[J].医学信息,2018,31(14):98.[doi:10.3969/j.issn.1006-1959.2018.14.028]
　LIU Jing-bo,HUANG Ping,ZHAO Jing.Study on the Health Management Model of Young and Middle-aged Patients with Type 2 Diabetes Mellitus by WeChat Platform[J].Journal of Medical Information,2018,31(09):98.[doi:10.3969/j.issn.1006-1959.2018.14.028]
[10]丁 星,赵 畅,张海严,等.麦邦数据远程传输型血糖仪临床测量准确性的评价研究[J].医学信息,2018,31(15):64.[doi:10.3969/j.issn.1006-1959.2018.15.020]
　DING Xing,ZHAO Chang,ZHANG Hai-yan,et al.Evaluation of Accuracy of Clinical Measurement of Maibang Remote Data Transmission Glucometer[J].Journal of Medical Information,2018,31(09):64.[doi:10.3969/j.issn.1006-1959.2018.15.020]

更新日期/Last Update: 2018-05-01